Patents Assigned to Biosite Diagnostics
-
Publication number: 20040096454Abstract: This invention provides a novel Cryptosporidium parvum protein disulfide isomerase polypeptide, and nucleic acids that encode this polypeptide. The invention also provides methods, reagents, and kits that are useful for diagnosing infection by Cryptosporidium parvum. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the protein disulfide isomerase polypeptide of C. parvum.Type: ApplicationFiled: June 7, 2001Publication date: May 20, 2004Applicant: Biosite Diagnostics, a Delaware corporationInventors: Jeff Gray, Gunars E. Valkirs, Joe Buechler
-
Publication number: 20040072241Abstract: This invention pertains to methods for detecting B. anthracis and antibodies to B.Type: ApplicationFiled: January 8, 2003Publication date: April 15, 2004Applicant: Biosite Diagnostics, a Delaware corporationInventors: Gunars Edwin Valkirs, Kenneth Buechler
-
Publication number: 20030129642Abstract: Disclosed is a fluorescent conjugate comprising a biological reagent, a fluorescent molecule, and a means for impeding phototoxic degradation of the biological reagent. The impeding means can be a cross-linking substance having a long molecular distance, whereby the cross-linking substance links the fluorescent molecule and the biological reagent; a quencher of singlet oxygen; a quencher of a free radical; or a combination thereof. Also disclosed is a solution comprising a fluorescent conjugate of a biological reagent and a fluorescent molecule together with an oxygen depleting system.Type: ApplicationFiled: January 7, 2003Publication date: July 10, 2003Applicant: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson, Alfred R. Sundquist
-
Publication number: 20030104477Abstract: The invention is directed to production of chimeric antibodies using display screening methods. The invention is based in part on two related but self-sufficient improvements in conventional display methods. The first improvement provides methods of enriching conventional display libraries for members displaying more than one copy of a polypeptide prior to affinity screening of such libraries with a target of interest. These methods can achieve diverse populations in which the vast majority of members retaining full-length coding sequences encode polypeptides having specific affinity for the target. In a second aspect, the invention provides methods of subcloning nucleic acids encoding displayed polypeptides of enriched libraries from a display vector to an expression vector without the need for clonal isolation of individual members. These methods can be used to produce polyclonal libraries of chimeric antibodies for use, e.g., as diagnostic or therapeutic reagents.Type: ApplicationFiled: July 12, 2002Publication date: June 5, 2003Applicant: Biosite Diagnostics, Inc.Inventors: Joe Buechler, Gunars Valkirs, Jeff Gray
-
Patent number: 6555310Abstract: The invention is directed to inter alia two related but self-sufficient improvements in conventional display methods. The first improvement provides methods of enriching conventional display libraries for members displaying more than one copy of a polypeptide prior to affinity screening of such libraries with a target of interest. These methods can achieve diverse populations in which the vast majority of members retaining full-length coding sequences encode polypeptides having specific affinity for the target. In a second aspect, the invention provides methods of subcloning nucleic acids encoding displayed polypeptides of enriched libraries from a display vector to an expression vector without the need for clonal isolation of individual members. These methods result in polyclonal libraries of antibodies and other polypeptides for use, e.g., as diagnostic or therapeutic reagents.Type: GrantFiled: April 4, 1997Date of Patent: April 29, 2003Assignee: Biosite Diagnostics, Inc.Inventors: Jeff Gray, Joe Buechler, Gunars Valkirs
-
Patent number: 6544797Abstract: Disclosed is a fluorescent conjugate comprising a biological reagent, a fluorescent molecule, and a means for impeding phototoxic degradation of the biological reagent. The impeding means can be a cross-linking substance having a long molecular distance, whereby the cross-linking substance links the fluorescent molecule and the biological reagent; a quencher of singlet oxygen; a quencher of a free radical; or a combination thereof. Also disclosed is a solution comprising a fluorescent conjugate of a biological reagent and a fluorescent molecule together with an oxygen depleting system.Type: GrantFiled: April 9, 1997Date of Patent: April 8, 2003Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson, Alfred R. Sundquist
-
Publication number: 20030064417Abstract: This invention provides methods, reagents, and kits that are useful for diagnosing infection by Giardia lamblia. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the &agr;-1-giardin antigen of G. lamblia.Type: ApplicationFiled: May 23, 2002Publication date: April 3, 2003Applicant: Biosite Diagnostics, a Delaware corporationInventors: Joe Buechler, Shanthi Govindaraj, Jeff Gray, Gunars E. Valkirs
-
Patent number: 6503722Abstract: This invention provides methods, compositions, and kits for detecting the presence of toxigenic strains of C. difficile in a biological sample. One embodiment provides methods for C. difficile detection that involve assaying for both C. difficile glutamate dehydrogenase and C. difficile toxin A or toxin B. In another embodiment, the invention provides a highly sensitive assay for C. difficile toxin A that is useful for determining whether a C. difficile strain is toxigenic. This embodiment involves binding of toxin A to a moiety that reversibly binds to a capture moiety present on a magnetic bead. A magnetic field is applied to the sample to concentrate the toxin A, after which the magnetic beads are dissociated and removed from the solution to obtain a highly concentrated preparation of toxin A, thus making possible a very sensitive assay.Type: GrantFiled: July 29, 1999Date of Patent: January 7, 2003Assignee: Biosite DiagnosticsInventor: Gunars E. Valkirs
-
Patent number: 6420113Abstract: The invention is directed to production of chimeric antibodies using display screening methods. The invention is based in part on two related but self-sufficient improvements in conventional display methods. The first improvement provides methods of enriching conventional display libraries for members displaying more than one copy of a polypeptide prior to affinity screening of such libraries with a target of interest. These methods can achieve diverse populations in which the vast majority of members retaining full-length coding sequences encode polypeptides having specific affinity for the target. In a second aspect, the invention provides methods of subcloning nucleic acids encoding displayed polypeptides of enriched libraries from a display vector to an expression vector without the need for clonal isolation of individual members. These methods can be used to produce polyclonal libraries of chimeric antibodies for use, e.g., as diagnostic or therapeutic reagents.Type: GrantFiled: October 2, 1999Date of Patent: July 16, 2002Assignee: Biosite Diagnostics, Inc.Inventors: Joe Buechler, Gunars Valkirs, Jeff Gray
-
Patent number: 6391265Abstract: Devices and use thereof, the device comprising a filter and a means for region specific compression of the filter. Alternatively, a single step assay device whereby fluid movement through the device occurs substantially solely due to action of capillary force, the device comprising a filter; a region containing the filter; a fluid access port to the region containing the filter; a means for retarding movement of particles through a peripheral filter surface; a fluid egress port from the region containing the filter; a lateral fluid flow path through the filter connecting the fluid access port to the fluid egress port, whereby sample fluid substantially devoid of particulate matter is released from the filter through the egress port; and, an exit region fluidly connected to the egress port.Type: GrantFiled: August 26, 1996Date of Patent: May 21, 2002Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth Francis Buechler, Richard Roger Batt
-
Patent number: 6348318Abstract: This invention provides methods, compositions and kits for concentrating target ligands, including microorganisms, from samples, including biological samples. The methods involve the use of magnetic particles to concentrate the target analytes. Also provided are methods, compositions and kits for detecting the presence of target ligands in samples.Type: GrantFiled: April 3, 1998Date of Patent: February 19, 2002Assignee: Biosite DiagnosticsInventor: Gunars E. Valkirs
-
Patent number: 6297060Abstract: Devices for use in heterogeneous ligand-receptor assays, having a porous member in contact with a nonabsorbent textured surface, where the surface texturing is such that a capillary network is formed when in fluid communication with the porous member. More particularly, these devices comprise: (a) a porous member having (i) at least one binding agent capable of immobilizing at least one target ligand on the porous member from a fluid sample in at least one zone and (ii) a means for detecting the presence or amount of said target ligand as a result of the assay process; and (b) a nonabsorbent member in fluid communication with the porous member, the nonabsorbent member forming at least one capillary with the porous member so that when sample, alone or in combination with other fluids, is added to the porous member, fluid is drawn through the porous member.Type: GrantFiled: February 11, 1999Date of Patent: October 2, 2001Assignee: Biosite Diagnostics, Inc.Inventors: Mark R. Nowakowski, Kenneth F. Buechler, Richard R. Anderson, Gunars E. Valkirs
-
Publication number: 20010021511Abstract: This invention provides methods, reagents, and kits that are useful for diagnosing infection by E. histolytica. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the 29 kDa antigen of E. histolytica.Type: ApplicationFiled: January 17, 2001Publication date: September 13, 2001Applicant: Biosite DiagnosticsInventors: Gunars E. Valkirs, Joe Buechler, Jeff Gray
-
Patent number: 6271040Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.Type: GrantFiled: July 30, 1997Date of Patent: August 7, 2001Assignee: Biosite Diagnostics IncorporatedInventor: Kenneth Francis Buechler
-
Patent number: 6251687Abstract: The invention describes the particles comprising an energy donor as a first component and a fluorescent dye as a second component positioned in said particles at an energy exchanging distance from one another, wherein the two components have a Stokes shift of greater than or equal to 50 nm, said particle having bound on its surface, a protein, polypeptide, nucleic acid, nucleotide or protein containing ligand analogue are disclosed and claimed. In addition, novel fluorescent dyes are described which exhibit intramolecular energy transfer for use to label various molecules, proteins, polypeptides, nucleotides and nucleic acids or to incorporate into particles.Type: GrantFiled: March 23, 1995Date of Patent: June 26, 2001Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Joseph Barry Noar, Lema Tadesse
-
Patent number: 6238931Abstract: Particles and methods for the detection or visualization of analytes using fluorescence energy transfer. Particles comprising an energy donor as a first component and a fluorescent dye as a second component positioned in said particles at an energy exchanging distance from one another, wherein the two components have a Stokes shift of greater than or equal to 50 nm, said particle having bound on its surface, a protein, polypeptide, nucleic acid, nucleotide or protein containing ligand analogue are disclosed and claimed.Type: GrantFiled: July 12, 1994Date of Patent: May 29, 2001Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Joseph Barry Noar, Lema Tadesse
-
Patent number: 6207395Abstract: This invention provides methods, reagents, and kits that are useful for diagnosing infection by E. histolytica. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the 29 kDa antigen of E. histolytica.Type: GrantFiled: September 21, 1998Date of Patent: March 27, 2001Assignee: Biosite Diagnostics, Inc.Inventors: Gunars E. Valkirs, Joe Buechler, Jeff Gray
-
Patent number: 6194222Abstract: The invention relates in part to the use of independent assay controls (IACs) for the optical communication between an assay device and an instrument in monitoring and performing assays, preferably immunoassays.Type: GrantFiled: January 5, 1998Date of Patent: February 27, 2001Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Joseph M Anderberg, Paul H. McPherson
-
Patent number: 6174686Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. Disclosed is a stabilized composition of troponin; the stabilized composition can comprise a stabilized composition of troponin I, wherein the troponin I is oxidized, the troponin I can be unbound or the troponin I can be in a complex.Type: GrantFiled: April 18, 1996Date of Patent: January 16, 2001Assignee: Biosite Diagnostics, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 6156270Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.Type: GrantFiled: March 27, 1997Date of Patent: December 5, 2000Assignee: Biosite Diagnostics, Inc.Inventor: Kenneth Francis Buechler